Entera Bio Ltd. (ENTX) Stock Price & Analysis
Entera Bio Ltd. (ENTX) rose 1.67% to USD 1.22 as of June 10, 2026 at 08:52 UTC, according to Nexqual real-time market data.
ENTX last closed at USD 1.2; the session ranged USD 1.18–1.23 on volume of 24,835 shares. Market capitalization is $60.13M, with a 52-week range of USD 0.91–3.22 (NCM). Source: Nexqual, June 10, 2026 at 08:52 UTC.
Key Statistics (as of June 10, 2026 at 08:52 UTC)
| Price | USD 1.22 |
|---|---|
| Change | ▲ 1.67% (up) |
| Previous Close | USD 1.2 |
| Open | USD 1.21 |
| Day Range | USD 1.18 – 1.23 |
| 52-Week Range | USD 0.91 – 3.22 |
| Volume | 24,835 shares |
| Market Cap | $60.13M |
| Exchange | NCM |
Technical Analysis (ENTX)
Nexqual's technical model rates ENTX "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 08:52 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 47.67 (neutral) |
| vs SMA50 | Above (USD 1.2) |
| MACD | -0 (negative) |
Analyst Ratings (ENTX)
Wall Street analysts rate ENTX "None" based on 1 analysts, with a mean price target of USD 9 (range USD 9–9), per Nexqual as of June 10, 2026 at 08:52 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 9 |
| High Target | USD 9 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (ENTX)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.07 vs est -0.08 ▲ beat |
| 2025-12-31 | USD -0.06 vs est -0.09 ▲ beat |
| 2025-09-30 | USD -0.07 vs est -0.09 ▲ beat |
| 2025-06-30 | USD -0.06 vs est -0.11 ▲ beat |
Source: Nexqual, June 10, 2026 at 08:52 UTC.
Financials & Fundamentals (ENTX)
| Total Revenue | $0 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -82.33% |
| Debt / Equity | 4.19 |
| Current Ratio | 7.93 |
| Total Cash | $4.14M |
| Total Debt | $448,000 |
| Free Cash Flow | $-4.84M |
Source: Nexqual, June 10, 2026 at 08:52 UTC.
Financial Health Score (ENTX)
Nexqual rates Entera Bio Ltd.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 08:52 UTC.
| Growth | Critical — Revenue -77% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $4M cash, no debt |
| Cash Flow | Weak — FCF negative: -$5M, burning cash |
| Efficiency | Critical — ROE -82%, ROA -45.0% |
Ownership (ENTX)
| Insider Ownership | +23.10% |
|---|---|
| Institutional Ownership | +15.98% |
| Shares Outstanding | 49.29M |
| Float | 40.36M |
| Short % of Float | +0.42% |
Source: Nexqual, June 10, 2026 at 08:52 UTC.
Leadership (ENTX)
Entera Bio Ltd. is led by Miranda J. Toledano (age 48), CEO & Director, per Nexqual as of June 10, 2026 at 08:52 UTC.
| CEO & Director | Miranda J. Toledano (age 48) |
|---|---|
| Chief Operating Officer | Hillel Galitzer (age 47) |
Major Backers & Investors (ENTX)
Notable institutional backers of Entera Bio Ltd. include Knoll Capital Management, LLC, Renaissance Technologies, Parkman Healthcare Partners LLC, according to Nexqual as of June 10, 2026 at 08:52 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Knoll Capital Management, LLC | 11.93% |
| Renaissance Technologies | 0.96% |
| Parkman Healthcare Partners LLC | 0.59% |
| Citadel | 0.5% |
| Seven Fleet Capital Management LP | 0.42% |
| Marshall Wace LLP | 0.4% |
| Xtx Topco Ltd | 0.27% |
| Schonfeld Strategic Advisors Llc | 0.11% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Northern Trust | 0.3% |
Source: Nexqual, June 10, 2026 at 08:52 UTC.
From Entera Bio Ltd.'s Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- All other provisions of the Patent Transfer Agreement remain in full force and effect.   Israeli Innovation Authority Grants   We have received grants of approximately $0.5 million from the IIA to partially fund our PTH research and development for Osteoporosis.  The grants are subject to certain requirements and restrictions under the Research Law.
Partnerships
- We intend to accelerate development and currently expect to submit an IND application to the FDA in late 2026.   80   EB618 Program (Oral GLP-1/Glucagon)   In September 2023, we entered into the 2023 Collaboration Agreement with OPKO Biologics.
- These data support the development of a once-daily oral PTH tablet for patients with hypoparathyroidism.   In February 2026, we announced the expansion of our collaboration with OPKO Biologics and OPKO to jointly advance this LA-PTH program.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VCNX | Vaccinex, Inc. | USD 1.19 | ▲ 19% |
| ATHE | Alterity Therapeutics Limited | USD 4.29 | ▲ 10% |
| IMMP | Immutep Limited | USD 0.37 | ▼ 2.92% |
| ENVB | Enveric Biosciences, Inc. | USD 1.6 | ▼ 11.11% |
| ADIL | Adial Pharmaceuticals, Inc | USD 2.13 | ▼ 3.62% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 08:52 UTC. This page is informational and not investment advice.